GlassScriptPhysician profile
Scott Douglas Beane
NPI 1659362804
$528.21
in general payments reported to CMS, 2019-2025
15 companies · $107 in 2025
The $107 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $18.89 · 2021: $91.52 · 2022: $64.78 · 2023: $98.29 · 2024: $40.40 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $94.85 | 2022-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $62.50 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $59.38 | 2019-2023 | Jornay Pm |
| Tris Pharma INC | $50.65 | 2019-2020 | |
| Pfizer INC. | $47.12 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $37.49 | 2021-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $36.25 | 2022-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Corium, LLC | $32.30 | 2022 | |
| Collegium Pharmaceutical, INC. | $19.10 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $18.08 | 2023 | |
| Shire North American Group INC | $15.61 | 2019 | |
| Novo Nordisk INC | $14.78 | 2025 | Wegovy |
| Cipher Pharmaceuticals US LLC | $14.44 | 2025 | Spinosad, Natroba |
| Glaxosmithkline, LLC. | $13.38 | 2023 | Bexsero, Pediarix |
| Genentech USA, INC. | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Beane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.